Get the Stockscreener App
5.32
1.10%
0.058
After Hours:
5.34
0.02
+0.38%
Bolt Biotherapeutics Inc stock is traded at $5.32, with a volume of 21,787.
It is up +1.10% in the last 24 hours and up +3.70% over the past month.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
See More
Previous Close:
$5.262
Open:
$5.24
24h Volume:
21,787
Relative Volume:
1.32
Market Cap:
$10.21M
Revenue:
$7.88M
Net Income/Loss:
$-69.20M
P/E Ratio:
-2.9071
EPS:
-1.83
Net Cash Flow:
$-69.73M
1W Performance:
-4.14%
1M Performance:
+3.70%
6M Performance:
-33.50%
1Y Performance:
-58.95%
1-Day Range:
$5.07
$5.4248
1-Week Range:
$5.07
$6.1999
52-Week Range:
$4.59
$14.36
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Name
Bolt Biotherapeutics Inc
Sector
Industry
Phone
650-665-9295
Address
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
5.32 | 10.10M | 7.88M | -69.20M | -69.73M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-02-21 | Initiated | Guggenheim | Buy |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
Bolt Biotherapeutics Inc Stock (BOLT) Latest News
Will Bolt Biotherapeutics Inc. (6LP0) stock benefit from Fed rate cutsWeekly Trade Report & Low Risk Investment Opportunities - newser.com
Will Bolt Biotherapeutics Inc. stock split attract more investorsBear Alert & Community Trade Idea Sharing - newser.com
Tools to monitor Bolt Biotherapeutics Inc. recovery probabilityTrade Ideas & Verified Technical Signals - newser.com
How Bolt Biotherapeutics Inc. (6LP0) stock correlates with oil markets2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Custom watchlist performance reports with Bolt Biotherapeutics Inc.Quarterly Risk Review & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Bolt Biotherapeutics Inc. stock maintain momentum in 2025Market Movement Recap & High Accuracy Buy Signal Tips - newser.com
Reversal indicators forming on Bolt Biotherapeutics Inc. stockMarket Risk Analysis & Stock Portfolio Risk Management - newser.com
Applying sector rotation models to Bolt Biotherapeutics Inc.Market Sentiment Review & Weekly High Return Stock Forecasts - newser.com
How Bolt Biotherapeutics Inc. stock reacts to inflationary pressuresWeekly Loss Report & Free Fast Gain Swing Trade Alerts - newser.com
Will Bolt Biotherapeutics Inc. (6LP0) stock issue positive guidanceJuly 2025 PostEarnings & Stepwise Entry and Exit Trade Signals - newser.com
Can Bolt Biotherapeutics Inc. (6LP0) stock test all time highsWeekly Market Summary & Safe Entry Zone Identification - newser.com
Real time breakdown of Bolt Biotherapeutics Inc. stock performanceQuarterly Portfolio Report & Trade Opportunity Analysis - newser.com
Published on: 2025-09-29 10:03:21 - newser.com
Published on: 2025-09-29 09:22:20 - newser.com
Historical volatility pattern of Bolt Biotherapeutics Inc. visualizedJuly 2025 Final Week & Verified Technical Signals - newser.com
Is Bolt Biotherapeutics Inc. stock overvalued by current metrics2025 Short Interest & Risk Adjusted Swing Trade Ideas - newser.com
What drives Bolt Biotherapeutics Inc 6LP0 stock priceREITs Market Trends & Capital Efficiency Improvement - earlytimes.in
Bolt Biotherapeutics Inc Stock (BOLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):